Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma

Narsis Attar, Rajib Shome, Mehmet Samur, Joshua Gustine, Charlotte Graham, Kathleen ME Gallagher, Agustin Busse, Deshea L Harris, Diana Cirstea, Andrew Yee, Andrew Branagan, Marcela Maus, Matthew Frigault, Nikhil Munshi, Adam Sperling, Noopur Raje

Blood (2025) 146 (Supplement 1): 5764.

https://doi.org/10.1182/blood-2025-5764

Published: 2025

Journal Articles

Venetoclax or pirtobrutinib in relapsed/refractory Waldenström macroglobulinemia: Clinical and molecular predictors and sequencing implications

Alberto Guijosa, Nickolas Tsakmaklis, Margaret Kobs, Nina Budano, Julia Nguyen, Alexandra Eurell, Maria Luisa Guerrera, Gottfried von Keudell, Andrew Branagan, Zachary Hunter, Steven Treon, Shayna Sarosiek, Jorge Castillo

Blood (2025) 146 (Supplement 1): 3577.

https://doi.org/10.1182/blood-2025-3577

Published: 2025

Journal Articles

Ruxolitinib for refractory immune effector cell enterocolitis following ciltacabtagene autoleucel CAR T-cell therapy for multiple myeloma

Blood (2025) 146 (Supplement 1): 2392.

https://doi.org/10.1182/blood-2025-2392

Published: 2025

Journal Articles

Deepening responses and MRD-conversion in a phase II fixed-duration consolidation trial of elranatamab post-idecabtagene vicleucel CAR-T cell therapy (EPIC) in relapsed or refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 5824.

https://doi.org/10.1182/blood-2025-5824

Published: 2025

Journal Articles

Discovery of an undocumented pattern of intron retention that is abundant in healthy B-cells and circumvented in Waldenstrom's macroglobulinemia impacting genes driving cellular growth and survival

Zachary Hunter, Amanda Kofides, Abigail Peachey, Nickolas Tsakmaklis, Maria Luisa Guerrera, Xia Liu, Shirong Liu, Hao Sun, Alberto Guijosa, John Hatcher, Dominic Pizzarella, Christopher Patterson, Andrew Branagan, Shayna Sarosiek, Jorge Castillo, Steven Treon

Blood (2025) 146 (Supplement 1): 3544.

https://doi.org/10.1182/blood-2025-3544

Published: 2025

Journal Articles

Regulatory network analysis identifies changes in ahr, TFAP4, and AP-1 transcription factors as top drivers of symptomatic disease progression in Waldenstrom's macroglobulinemia.

Blood (2025) 146 (Supplement 1): 3543.

https://doi.org/10.1182/blood-2025-3543

Published: 2025

Journal Articles

Validation and refinement of the new high-risk multiple myeloma (HRMM) criteria in relapsed or refractory patients treated with BCMA CAR-T.

Joshua Gustine, Narsis Attar, Benjamin Puliafito, Diana Cirstea, Andrew Branagan, Marcela Maus, Matthew Frigault, Andrew Yee, Noopur Raje

Blood (2025) 146 (Supplement 1): 2243.

https://doi.org/10.1182/blood-2025-2243

Published: 2025

Journal Articles

Mass spectrometry demonstrates very frequent multi-clonality in familial Waldenström macroglobulinemia and shows distinct IgM profiles across IgM-related disorders.

Alberto Guijosa, Nickolas Tsakmaklis, Abigail Peachey, Nicholas Paciaroni, Nina Budano, Julia Nguyen, Kirsten Meid, Maria Luisa Guerrera, Christopher Patterson, Andrew Branagan, Shayna Sarosiek, Zachary Hunter, Jorge Castillo, Steven Treon

Blood (2025) 146 (Supplement 1): 5392.

https://doi.org/10.1182/blood-2025-5392

Published: 2025

Journal Articles

Final report of a phase II study of ibrutinib and venetoclax in previously untreated Waldenström macroglobulinemia

Jorge Castillo, Andrew Branagan, Gottfried von Keudell, Alberto Guijosa, Nina Budano, Julia Nguyen, Alexandra Eurell, Kirsten Meid, Maria Luisa Guerrera, Amanda Kofides, Shirong Liu, Xia Liu, Nickolas Tsakmaklis, Zachary Hunter, Steven Treon, Shayna Sarosiek

Blood (2025) 146 (Supplement 1): 1794.

https://doi.org/10.1182/blood-2025-1794

Published: 2025

Journal Articles

LOX1 expression identifies a population of polymorphonuclear myeloid-derived suppressor cells that are highly enriched in bone marrow samples of treatment-Naïve and BTKi-Relapsed/Refractory WM patients and show constitutive activation of BTK

Blood (2025) 146 (Supplement 1): 5731.

https://doi.org/10.1182/blood-2025-5731

Published: 2025

Journal Articles

Deep responses following treatment with loncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those withhigh-risk, TP53-altered Waldenström macroglobulinemia.

Shayna Sarosiek, Mary Kwok, Prashant Kapoor, Hannah Chory, Nina Budano, Julia Nguyen, Alexandra Eurell, Kirsten Meid, Alberto Guijosa, Nickolas Tsakmaklis, Zachary Hunter, Andrew Branagan, Steven Treon, Jorge Castillo

Blood (2025) 146 (Supplement 1): 581.

https://doi.org/10.1182/blood-2025-581

Published: 2025

Journal Articles

High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study

Blood (2025) 146 (Supplement 1): 225.

https://doi.org/10.1182/blood-2025-225

Published: 2025

Journal Articles

Double-hit alterations of TP53 identify ultra high-risk disease in previously treated, MYD88 mutated waldenstrom macroglobulinemia.

Nickolas Tsakmaklis, Alberto Guijosa, Andres Ramirez, Amanda Kofides, Abigail Peachey, Xia Liu, Hao Sun, Maria Luisa Guerrera, Christopher Patterson, Andrew Branagan, Shayna Sarosiek, Jorge Castillo, Zachary Hunter, Steven Treon

Blood (2025) 146 (Supplement 1): 224.

https://doi.org/10.1182/blood-2025-224

Published: 2025

Journal Articles

First-in-human phase 1 trial of trimeric APRIL (TriPRIL) CAR T cells in relapsed or refractory multiple myeloma: Clinical outcomes and biological correlates of disease response and resistance

Blood (2025) 146 (Supplement 1): 270.

https://doi.org/10.1182/blood-2025-270

Published: 2025

Journal Articles

Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma

Blood (2025) 146 (Supplement 1): 503.

https://doi.org/10.1182/blood-2025-503

Published: 2025

Journal Articles

Risk score and survival outcomes for multiple myeloma patients with disease refractory to BCMA CAR-T.

Joshua Gustine, Narsis Attar, Benjamin Puliafito, Diana Cirstea, Andrew Branagan, Marcela Maus, Matthew Frigault, Andrew Yee, Noopur Raje

Blood (2025) 146 (Supplement 1): 5792.

https://doi.org/10.1182/blood-2025-5792

Published: 2025

Journal Articles

CD20 (MS4A1) mutations are strongly associated with prior chemoimmunotherapy exposure in Waldenström macroglobulinemia and have predicted functional consequences for the development of CD20-directed cellular therapies.

Alberto Guijosa, Nickolas Tsakmaklis, Sirano Dhe-Paganon, John Hatcher, Andres Ramirez, Dominic Pizzarella, Amanda Kofides, Abigail Peachey, Shirong Liu, Hao Sun, Xia Liu, Maria Luisa Guerrera, Andrew Branagan, Gottfried von Keudell, Shayna Sarosiek, Jorge Castillo, Zachary Hunter, Steven Treon

Blood (2025) 146 (Supplement 1): 3611.

https://doi.org/10.1182/blood-2025-3611

Published: 2025

Journal Articles

Two Dose Series of High-Dose Influenza Vaccine Is Associated with Longer Duration of Serologic Immunity in Patients with Plasma Cell Disorders

Andrew Branagan, MD, Eamon Duffy, Connor Foster, Rakesh Verma, PhD, Lin Zhang, PhD, Geliang Gan, PhD, Fangyong Li, PhD, Madhav V Dhodapkar, MBBS

Blood (2017) 130 (Supplement 1): 438.

https://doi.org/10.1182/blood.V130.Suppl_1.438.438

Published: 2017

Journal Articles

Long Term Responses to Fludarabine and Rituximab in Waldenstrom’s Macroglobulinemia

Steven Treon, MD, PhD, Andrew Branagan, Leukothea Ioakimidis, PhD, Jacob Soumerai, Christopher Patterson, MD, Parveen Wasi, MD, FRCP(C), Christos Emmanouilides, MD, PhD, Stanley R. Frankel, MD, T. Andrew Lister, MD, Pierre Morel, MD, Jeffrey Matous, MD, Stephanie A. Gregory, MD, Eva K. Kimby, MD, PhD

Blood (2008) 112 (11): 3057.

https://doi.org/10.1182/blood.V112.11.3057.3057

Published: 2008

Journal Articles

A Novel Functional Role for Soluble CD27 in the Pathogenesis of Waldenstrom’s Macroglobulinemia.

Allen W. Ho, Xavier Leleu, MD, Evdoxia Hatjiharissi, MD, Olivier Tournilhac, MD, Lian Xu, Kelly O’Connor, Robert Manning, Daniel Santos, MD, Mariana Chemaly, MD, Andrew Branagan, Zachary Hunter, Christopher Patterson, Kenneth C. Anderson, MD, Steven P. Treon, MD, PhD

Blood (2005) 106 (11): 4701.

https://doi.org/10.1182/blood.V106.11.4701.4701

Published: 2005

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma

Venetoclax or pirtobrutinib in relapsed/refractory Waldenström macroglobulinemia: Clinical and molecular predictors and sequencing implications

Ruxolitinib for refractory immune effector cell enterocolitis following ciltacabtagene autoleucel CAR T-cell therapy for multiple myeloma

Deepening responses and MRD-conversion in a phase II fixed-duration consolidation trial of elranatamab post-idecabtagene vicleucel CAR-T cell therapy (EPIC) in relapsed or refractory multiple myeloma

Discovery of an undocumented pattern of intron retention that is abundant in healthy B-cells and circumvented in Waldenstrom's macroglobulinemia impacting genes driving cellular growth and survival

Regulatory network analysis identifies changes in ahr, TFAP4, and AP-1 transcription factors as top drivers of symptomatic disease progression in Waldenstrom's macroglobulinemia.

Validation and refinement of the new high-risk multiple myeloma (HRMM) criteria in relapsed or refractory patients treated with BCMA CAR-T.

Mass spectrometry demonstrates very frequent multi-clonality in familial Waldenström macroglobulinemia and shows distinct IgM profiles across IgM-related disorders.

Final report of a phase II study of ibrutinib and venetoclax in previously untreated Waldenström macroglobulinemia

LOX1 expression identifies a population of polymorphonuclear myeloid-derived suppressor cells that are highly enriched in bone marrow samples of treatment-Naïve and BTKi-Relapsed/Refractory WM patients and show constitutive activation of BTK

Deep responses following treatment with loncastuximab tesirine (WM-NET1 trial) in patients with Relapsed/Refractory including those withhigh-risk, TP53-altered Waldenström macroglobulinemia.

High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study

Double-hit alterations of TP53 identify ultra high-risk disease in previously treated, MYD88 mutated waldenstrom macroglobulinemia.

First-in-human phase 1 trial of trimeric APRIL (TriPRIL) CAR T cells in relapsed or refractory multiple myeloma: Clinical outcomes and biological correlates of disease response and resistance

Single-cell transcriptomics reveal mechanisms of efficacy and toxicity in anti-BCMA CAR-T cell therapies for multiple myeloma

Risk score and survival outcomes for multiple myeloma patients with disease refractory to BCMA CAR-T.

CD20 (MS4A1) mutations are strongly associated with prior chemoimmunotherapy exposure in Waldenström macroglobulinemia and have predicted functional consequences for the development of CD20-directed cellular therapies.

Two Dose Series of High-Dose Influenza Vaccine Is Associated with Longer Duration of Serologic Immunity in Patients with Plasma Cell Disorders

Long Term Responses to Fludarabine and Rituximab in Waldenstrom’s Macroglobulinemia

A Novel Functional Role for Soluble CD27 in the Pathogenesis of Waldenstrom’s Macroglobulinemia.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only